The vulnerable endothelium: priming the vascular endothelium for thrombosis with unfractionated heparin: biologic plausibility for observations from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial (Am J Heart 2005;150:189-92)

To the Editor: In this splendid commentary, a biologically plausible rationale for attenuation of benefits of enoxaparin in patients undergoing percutaneous coronary intervention in the SYNERGY trial is presented.1 Patients who received pretreatment with unfractionated heparin (UFH) and then crossed...

Full description

Saved in:
Bibliographic Details
Published in:The American heart journal 2006-05, Vol.151 (5), p.e3-e3
Main Author: Aggarwal, Atul
Format: Article
Language:English
Subjects:
Angioplasty, Balloon, Coronary
Anticoagulants - administration & dosage
Anticoagulants - adverse effects
Anticoagulants - therapeutic use
Cardiology
Drug Administration Schedule
Drug therapy
Drug Therapy, Combination
Endothelium
Endothelium, Vascular - drug effects
Enoxaparin - therapeutic use
Heart attacks
Heparin - administration & dosage
Heparin - adverse effects
Heparin - therapeutic use
Hirudins
Humans
Myocardial Infarction - chemically induced
Peptide Fragments - therapeutic use
Recombinant Proteins - therapeutic use
Thrombophilia - prevention & control
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To the Editor: In this splendid commentary, a biologically plausible rationale for attenuation of benefits of enoxaparin in patients undergoing percutaneous coronary intervention in the SYNERGY trial is presented.1 Patients who received pretreatment with unfractionated heparin (UFH) and then crossed over to receive enoxaparin for the purpose of percutaneous coronary intervention possibly enfeebled the benefits of this strategy for the achievement of the primary end point (demonstrating superiority of enoxaparin over UFH).
ISSN:0002-8703
1097-6744
DOI:10.1016/j.ahj.2005.09.027